TY - JOUR T1 - PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH CHILDREN JF - medRxiv DO - 10.1101/2020.05.14.20097188 SP - 2020.05.14.20097188 AU - María Fátima Ara-Montojo AU - Luis Escosa-García AU - Marina Alguacil AU - Nieves Seara AU - Carlos Zozaya AU - Diego Plaza AU - Cristina Schuffelmann-Gutiérrez AU - Ángela de la Vega AU - Carlota Fernández-Camblor AU - Esther Ramos-Boluda AU - María Pilar Romero-Gómez AU - Guillermo Ruiz-Carrascoso AU - Itsaso Losantos-García AU - María José Mellado-Peña AU - Rosa Gómez-Gil Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/18/2020.05.14.20097188.abstract N2 - Background Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in pediatric population worldwide with high mortality rates (18.5-52%) in bloodstream infection (BSI).Objectives The aim of this study is to evaluate predictors of 30-day mortality in CRE BSI in a pediatric cohort.Methods Retrospective observational single-center study (December 2005 - August 2018) was conducted. CRE BSI in children 0 to 16 years were included. Microbiological identification (MALDI Biotyper) and antimicrobial susceptibility testing (Vitek2® and MicroScan panel NBC44) according to current EUCAST breakpoints were performed. PCR OXVIKP® was used to confirm carbapenemases genes (OXA-48, VIM, KPC, NDM). Demographic characteristics, underlying diseases, source of bacteremia, antimicrobial therapy and outcomes were collected from medical records. Survival analysis to establish predictors of 30 day-mortality was performed.Results Thirty-eight cases were included, 76.3% hospital-acquired infections and 23.7% related to healthcare. All patients had underlying comorbidity and 52.6% had received a transplant. VIM-carbapenemase was the predominant mechanism (92%). Previous CRE colonization or infection rate was 52.6%. Gut (26%) and vascular catheter (21%) were the predominant sources of infection. Crude mortality within 30 days was 18.4% (7/38); directly related 30-day mortality was 10.5%. Conditions associated with an increment in 30-day mortality were intensive care admission and inadequate empiric therapy (p<0.05). Combination antibiotic targeted treatment and a low meropenem MIC were not related to improved survival.Conclusions CRE BSI mortality rate is high. The most important factor related to 30-day survival in our CRE BSI cohort in children was success in empiric treatment with at least one active antibiotic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not economical supported by any institution.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collected patients data from medical records in an anonymized Excel database. ER -